17 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2037
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2039 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Nov 2037 · High confidence
Combination Therapies and Uses Thereof
US 11,801,240
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039.
Methods of Manufacturing of Niraparib
US 11,161,834
The earliest of the three still in force, granted 2021 and renewed since. Its term ends first, in 2038.
Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
US 11,753,472
A family of 5 related applications built on the 2023 grant. Protection runs to 2037.
Formerly held, still cited
Notable
Ends Mar 2038 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
now held by Merck Sharp & Dohme LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Combination Therapies for Treating Cancer with Niraparib and PD-1 Inhibitors (US 11,661,453) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Niraparib Formulations (US 11,730,725) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) (US 11,753,472) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Combination Therapies and Uses Thereof (US 11,801,240) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Methods of Treating Cancer with ANTI-TIM-3 Antibodies (US 11,926,665) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Treating Cancer with ANTI-PD-1 Antibodies | 2 in force | to Aug 2038 |
| Methods of Manufacturing of Niraparib | 2 in force | to Apr 2038 |
| Methods of Treating Ovarian Cancer | 2 in force | to Jun 2037 |
| Methods for Characterizing and Treating a Cancer Type Using Cancer Images | 1 in force | to Oct 2042 |
| Niraparib Salts | 1 in force | to Feb 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,383,542 | Methods of Treating Ovarian Cancer In force · High confidence | In force | High confidence | |
| US 12,527,780 | Methods of Treating Ovarian Cancer In force · High confidence | In force | High confidence | |
| US 11,753,472 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) In force · High confidence | In force | High confidence | |
| US 12,415,855 | Methods of Treating Cancer with ANTI-PD-1 Antibodies In force · High confidence | In force | High confidence | |
| US 11,161,834 | Methods of Manufacturing of Niraparib In force · High confidence | In force | High confidence | |
| US 11,629,137 | Methods of Manufacturing of Niraparib In force · High confidence | In force | High confidence | |
| US 11,622,961 | Combination Therapies for Treating Cancer In force · High confidence | In force | High confidence | |
| US 11,155,624 | Antibodies Directed Against Programmed Death- 1 (PD-1) held by Anaptysbio, Inc. and Tesaro, Inc. In force · High confidence | In force | High confidence | |
| US 11,407,830 | Methods of Treating Cancer with ANTI-PD-1 Antibodies In force · High confidence | In force | High confidence | |
| US 10,927,077 | Process for Preparing Intermediate of Anti-Tumor Drug Niraparib and Intermediate Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 2 patents in force now held by others · 15 applications pending · 17 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.